Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 AUD | -.--% | -21.74% | -48.57% |
May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 23-07-11 |
Chief Tech/Sci/R&D Officer | - | 22-07-04 | |
Li Ren
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-24 |
Jason B. Litten
CTO | Chief Tech/Sci/R&D Officer | 50 | 22-07-24 |
Elizabeth Chang
PRN | Corporate Officer/Principal | - | - |
Eliot Bourk
PRN | Corporate Officer/Principal | - | 21-02-22 |
Nathan Jong
SEC | Corporate Secretary | - | - |
Alison Gartner
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | 60 | 22-02-02 | |
Corporate Officer/Principal | 63 | 22-08-07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lesley Russell
BRD | Director/Board Member | 63 | 20-08-27 |
Paul Hopper
FOU | Founder | 68 | 20-02-01 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 23-07-11 |
Eric Sullivan
BRD | Director/Board Member | - | 23-08-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 725,840,586 | 652,667,576 ( 89.92 %) | 0 | 89.92 % |
Company contact information
Chimeric Therapeutics Ltd. (Australia)
62 Lygon Street Level 3
3053, Carlton
+
http://www.chimerictherapeutics.comSector
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-48.57% | 10.24M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- CHM Stock
- Company Chimeric Therapeutics Limited